A citation-based method for searching scientific literature

Marcos Garcia-Lacarte, Sara C Grijalba, Javier Melchor, Adrián Arnaiz-Leché, Sergio Roa. Cancers (Basel) 2021
Times Cited: 3







List of co-cited articles
18 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.
Lauren C Chong, David D W Twa, Anja Mottok, Susana Ben-Neriah, Bruce W Woolcock, Yongjun Zhao, Kerry J Savage, Marco A Marra, David W Scott, Randy D Gascoyne,[...]. Blood 2016
40
66

PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Wei Xie, L Jeffrey Medeiros, Shaoying Li, C Cameron Yin, Joseph D Khoury, Jie Xu. Curr Hematol Malig Rep 2020
24
66

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Dohee Kwon, Sehui Kim, Pil-Jong Kim, Heounjeong Go, Soo Jeong Nam, Jin Ho Paik, Young A Kim, Tae Min Kim, Dae Seog Heo, Chul Woo Kim,[...]. Histopathology 2016
109
66

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, Scott J Rodig, Przemyslaw Juszczynski, Treeve Currie, Evan O'Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R Golub,[...]. Blood 2010
844
66

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Michael R Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A Shipp. Clin Cancer Res 2012
476
66

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, Seiji Sakata, Misako Matsumoto, Seiji Nagano, Takuya Maeda, Yasunobu Nagata, Akira Kitanaka, Seiya Mizuno,[...]. Nature 2016
403
66

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
270
66

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Konstantinos Georgiou, Longyun Chen, Mattias Berglund, Weicheng Ren, Noel F C C de Miranda, Susana Lisboa, Marco Fangazio, Shida Zhu, Yong Hou, Kui Wu,[...]. Blood 2016
131
66

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
Michal Marzec, Qian Zhang, Ami Goradia, Puthiyaveettil N Raghunath, Xiaobin Liu, Michele Paessler, Hong Yi Wang, Maria Wysocka, Mangeng Cheng, Bruce A Ruggeri,[...]. Proc Natl Acad Sci U S A 2008
520
66

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Wei Xing, Karen Dresser, Rui Zhang, Andrew M Evens, Hongbo Yu, Bruce A Woda, Benjamin J Chen. Oncotarget 2016
45
66

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Heather Homer, Courtney F Connelly, Heather H Sun, Sarah E Daadi, Gordon J Freeman,[...]. J Clin Oncol 2016
483
66

PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
Jing Shen, Shaoying Li, L Jeffrey Medeiros, Pei Lin, Sa A Wang, Guilin Tang, C Cameron Yin, M James You, Joseph D Khoury, Swaminathan P Iyer,[...]. Mod Pathol 2020
24
66

Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Yi Xia, L Jeffrey Medeiros, Ken H Young. Blood Rev 2016
27
66

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp,[...]. Clin Cancer Res 2013
582
66

EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.
Alina Nicolae, Stefania Pittaluga, Shahed Abdullah, Seth M Steinberg, Thu Anh Pham, Theresa Davies-Hill, Liqiang Xi, Mark Raffeld, Elaine S Jaffe. Blood 2015
163
66

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.
V Atsaves, N Tsesmetzis, D Chioureas, L Kis, V Leventaki, E Drakos, T Panaretakis, D Grander, L J Medeiros, K H Young,[...]. Leukemia 2017
117
66

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.
Rebecca A Luchtel, Surendra Dasari, Naoki Oishi, Martin Bjerregård Pedersen, Guangzhen Hu, Karen L Rech, Rhett P Ketterling, Jagmohan Sidhu, Xueju Wang, Ryohei Katoh,[...]. Blood 2018
56
66

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe,[...]. Blood 2015
316
66

Role of PD-1 in regulating T-cell immunity.
Hyun-Tak Jin, Rafi Ahmed, Taku Okazaki. Curr Top Microbiol Immunol 2011
208
33

Revised International Pediatric Non-Hodgkin Lymphoma Staging System.
Angelo Rosolen, Sherrie L Perkins, C Ross Pinkerton, R Paul Guillerman, John T Sandlund, Catherine Patte, Alfred Reiter, Mitchell S Cairo. J Clin Oncol 2015
72
33

Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Cancer Res 2015
910
33

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Zijun Y Xu-Monette, Jianyong Li, Yi Xia, Beryl Crossley, Robert D Bremel, Yi Miao, Min Xiao, Thomas Snyder, Ganiraju C Manyam, Xiaohong Tan,[...]. J Immunother Cancer 2019
13
33

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.
Nikita Kotlov, Alexander Bagaev, Maria V Revuelta, Jude M Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina,[...]. Cancer Discov 2021
49
33

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ikuo Konishi. Int J Clin Oncol 2016
191
33

Expression of PD-L1 in EBV-associated malignancies.
Xiaoxu Li, Wenling Zhang. Int Immunopharmacol 2021
8
33

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
561
33

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V Marshall, Catherine Vezina, Alberto Pappo, Theodore W Laetsch, Antonio S Petrilli, Martin Ebinger, Jacek Toporski,[...]. Lancet Oncol 2020
104
33


PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Mark Yarchoan, Lee A Albacker, Alexander C Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena T Vithayathil, Neeha Zaidi, Nilofer S Azad, Daniel A Laheru, Garrett M Frampton,[...]. JCI Insight 2019
218
33

Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll. Cancer Cell 2015
33

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
Volker Endris, Ivo Buchhalter, Michael Allgäuer, Eugen Rempel, Amelie Lier, Anna-Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring, Olaf Neumann,[...]. Int J Cancer 2019
67
33

Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Luis Veloza, Cristina Teixido, Natalia Castrejon, Fina Climent, Ana Carrió, Marta Marginet, Davide Soldini, Blanca González-Farré, Inmaculada Ribera-Cortada, Armando Lopez-Guillermo,[...]. Histopathology 2019
24
33

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
809
33

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Kara L Davis, Elizabeth Fox, Melinda S Merchant, Joel M Reid, Rachel A Kudgus, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel,[...]. Lancet Oncol 2020
114
33

PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.
Ana-Iris Schiefer, Elisabeth Salzer, Anna Füreder, Zsolt Szepfalusi, Thomas Müller-Sacherer, Wolf-Dietrich Huber, Ina Michel-Behnke, Anita Lawitschka, Herbert Pichler, Georg Mann,[...]. Cancer Med 2019
9
33


Checkpoint inhibition in pediatric hematologic malignancies.
Kara L Davis, Archana M Agarwal, Anupam R Verma. Pediatr Hematol Oncol 2017
15
33

PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol 2008
33

Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Amelie Kinch, Christer Sundström, Eva Baecklund, Carin Backlin, Daniel Molin, Gunilla Enblad. Leuk Lymphoma 2019
21
33


Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.
Lisa Giulino-Roth, Kai Wang, Theresa Y MacDonald, Susan Mathew, Yifang Tam, Maureen T Cronin, Gary Palmer, Norma Lucena-Silva, Francisco Pedrosa, Marcia Pedrosa,[...]. Blood 2012
70
33


Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Yi Xia, L Jeffrey Medeiros, Ken H Young. Biochim Biophys Acta 2016
48
33

Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.
Ivo Buchhalter, Eugen Rempel, Volker Endris, Michael Allgäuer, Olaf Neumann, Anna-Lena Volckmar, Martina Kirchner, Jonas Leichsenring, Amelie Lier, Moritz von Winterfeld,[...]. Int J Cancer 2019
95
33

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
33


Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis.
Ting Zhou, M Suzanne Bloomquist, Lizmery Suarez Ferguson, Jacquelyn Reuther, Andrea N Marcogliese, M Tarek Elghetany, Angshumoy Roy, Pulivarthi H Rao, Dolores H Lopez-Terrada, Michele S Redell,[...]. Pediatr Hematol Oncol 2020
11
33

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
33

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.
Adam Shlien, Brittany B Campbell, Richard de Borja, Ludmil B Alexandrov, Daniele Merico, David Wedge, Peter Van Loo, Patrick S Tarpey, Paul Coupland, Sam Behjati,[...]. Nat Genet 2015
221
33

PD-L1 and tumor-associated macrophages in de novo DLBCL.
Ronald McCord, Christopher R Bolen, Hartmut Koeppen, Edward E Kadel, Mikkel Z Oestergaard, Tina Nielsen, Laurie H Sehn, Jeffrey M Venstrom. Blood Adv 2019
45
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.